Left ventricular device implantation for advanced cardiac amyloidosis

Paul L. Swiecicki, Brooks Sayre Edwards, Sudhir S. Kushwaha, Angela Dispenzieri, Soon J. Park, Morie Gertz

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The purpose of this study was to analyze the post-hospital outcomes in patients with senile or familial cardiac amyloidosis treated with left ventricular assist device (LVAD) implantation. From December 1, 2008 to May 31, 2012, a total of 9 patients underwent LVAD placement for heart failure secondary to amyloidosis. Prior to LVAD placement, all patients were New York Heart Association (NYHA) Class IV and had a significantly decreased cardiac index (mean 1.93 liters/min/m2 [1.64 to 2.36]). All patients tolerated LVAD implantation well. Post-operatively, 2 patients died prior to hospital discharge. Three patients died since discharge with a median survival of 13.7 months. Four patients remained alive with a follow-up of 16-24 months. The most common adverse event since placement has been gastrointestinal bleeding (3 of 9 patients). Firm conclusions cannot be drawn from our investigation, but the present observations suggest LVAD implantation is technically feasible for patients with severe heart failure due to advanced cardiac amyloidosis.

Original languageEnglish (US)
Pages (from-to)563-568
Number of pages6
JournalJournal of Heart and Lung Transplantation
Volume32
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Amyloidosis
Heart-Assist Devices
Equipment and Supplies
Heart Failure
Familial Amyloidosis
Hemorrhage
Survival

Keywords

  • cardiac amyloidosis;
  • familial amyloidosis
  • left ventricular assist device;
  • light chain amyloidosis;
  • restrictive cardiomyopathy;
  • senile amyloidosis;

ASJC Scopus subject areas

  • Transplantation
  • Cardiology and Cardiovascular Medicine
  • Pulmonary and Respiratory Medicine
  • Surgery

Cite this

Left ventricular device implantation for advanced cardiac amyloidosis. / Swiecicki, Paul L.; Edwards, Brooks Sayre; Kushwaha, Sudhir S.; Dispenzieri, Angela; Park, Soon J.; Gertz, Morie.

In: Journal of Heart and Lung Transplantation, Vol. 32, No. 5, 05.2013, p. 563-568.

Research output: Contribution to journalArticle

@article{4335c42f02614aa191688a06ddc4b256,
title = "Left ventricular device implantation for advanced cardiac amyloidosis",
abstract = "The purpose of this study was to analyze the post-hospital outcomes in patients with senile or familial cardiac amyloidosis treated with left ventricular assist device (LVAD) implantation. From December 1, 2008 to May 31, 2012, a total of 9 patients underwent LVAD placement for heart failure secondary to amyloidosis. Prior to LVAD placement, all patients were New York Heart Association (NYHA) Class IV and had a significantly decreased cardiac index (mean 1.93 liters/min/m2 [1.64 to 2.36]). All patients tolerated LVAD implantation well. Post-operatively, 2 patients died prior to hospital discharge. Three patients died since discharge with a median survival of 13.7 months. Four patients remained alive with a follow-up of 16-24 months. The most common adverse event since placement has been gastrointestinal bleeding (3 of 9 patients). Firm conclusions cannot be drawn from our investigation, but the present observations suggest LVAD implantation is technically feasible for patients with severe heart failure due to advanced cardiac amyloidosis.",
keywords = "cardiac amyloidosis;, familial amyloidosis, left ventricular assist device;, light chain amyloidosis;, restrictive cardiomyopathy;, senile amyloidosis;",
author = "Swiecicki, {Paul L.} and Edwards, {Brooks Sayre} and Kushwaha, {Sudhir S.} and Angela Dispenzieri and Park, {Soon J.} and Morie Gertz",
year = "2013",
month = "5",
doi = "10.1016/j.healun.2013.01.987",
language = "English (US)",
volume = "32",
pages = "563--568",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Left ventricular device implantation for advanced cardiac amyloidosis

AU - Swiecicki, Paul L.

AU - Edwards, Brooks Sayre

AU - Kushwaha, Sudhir S.

AU - Dispenzieri, Angela

AU - Park, Soon J.

AU - Gertz, Morie

PY - 2013/5

Y1 - 2013/5

N2 - The purpose of this study was to analyze the post-hospital outcomes in patients with senile or familial cardiac amyloidosis treated with left ventricular assist device (LVAD) implantation. From December 1, 2008 to May 31, 2012, a total of 9 patients underwent LVAD placement for heart failure secondary to amyloidosis. Prior to LVAD placement, all patients were New York Heart Association (NYHA) Class IV and had a significantly decreased cardiac index (mean 1.93 liters/min/m2 [1.64 to 2.36]). All patients tolerated LVAD implantation well. Post-operatively, 2 patients died prior to hospital discharge. Three patients died since discharge with a median survival of 13.7 months. Four patients remained alive with a follow-up of 16-24 months. The most common adverse event since placement has been gastrointestinal bleeding (3 of 9 patients). Firm conclusions cannot be drawn from our investigation, but the present observations suggest LVAD implantation is technically feasible for patients with severe heart failure due to advanced cardiac amyloidosis.

AB - The purpose of this study was to analyze the post-hospital outcomes in patients with senile or familial cardiac amyloidosis treated with left ventricular assist device (LVAD) implantation. From December 1, 2008 to May 31, 2012, a total of 9 patients underwent LVAD placement for heart failure secondary to amyloidosis. Prior to LVAD placement, all patients were New York Heart Association (NYHA) Class IV and had a significantly decreased cardiac index (mean 1.93 liters/min/m2 [1.64 to 2.36]). All patients tolerated LVAD implantation well. Post-operatively, 2 patients died prior to hospital discharge. Three patients died since discharge with a median survival of 13.7 months. Four patients remained alive with a follow-up of 16-24 months. The most common adverse event since placement has been gastrointestinal bleeding (3 of 9 patients). Firm conclusions cannot be drawn from our investigation, but the present observations suggest LVAD implantation is technically feasible for patients with severe heart failure due to advanced cardiac amyloidosis.

KW - cardiac amyloidosis;

KW - familial amyloidosis

KW - left ventricular assist device;

KW - light chain amyloidosis;

KW - restrictive cardiomyopathy;

KW - senile amyloidosis;

UR - http://www.scopus.com/inward/record.url?scp=84876045920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876045920&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2013.01.987

DO - 10.1016/j.healun.2013.01.987

M3 - Article

C2 - 23474361

AN - SCOPUS:84876045920

VL - 32

SP - 563

EP - 568

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 5

ER -